Zhejiang Ausun Pharmaceutical Co., Ltd. (China)

Zhejiang Ausun Pharmaceutical Co., Ltd. is a pharmaceutical company located in Taizhou, Zhejiang Province. It was incorporated in April 2010 and listed on the Shanghai Stock Exchange on May 9, 2017, with the stock code 603229. The company operates in the Taizhou Bay Economic and Technological Development Zone and is recognized as a national high-tech enterprise. It has established a national post-doctoral workstation, as well as platforms such as the Zhejiang Provincial Key Enterprise Research Institute, Provincial Enterprise Technology Center, and Provincial R&D Center. The company currently has over 1,000 employees, including a research and development team of more than 300 people consisting of doctors and masters. Zhejiang Ausun Pharmaceutical is primarily engaged in the research, production, and sales of pharmaceutical formulations, specialty APIs, and pharmaceutical intermediates. It also provides customized processing and research and development services to its customers. The company's products are mainly exported to countries and regions such as Europe, the United States, Japan, and South Korea. In 2022, the company's operating income increased by 34.2% year-on-year, and net profit increased by 61.29% year-on-year. The company's products are categorized into eight major classes, including liver disease, respiratory system, cardiovascular system, high-end fluorine products, prostaglandins, antibacterials, gout, and anti-tumor. These products have complex chiral structures, high research and development difficulty, and unique production processes, resulting in high technological barriers. Zhejiang Ausun Pharmaceutical attaches great importance to technological innovation and research and development, with research and development investment accounting for more than 10% of its operating income in the past three years. The company focuses on the health industry and adheres to the core concept of "quality + innovation." Its corporate mission is to "serve health and create the future." Following the requirements of China's pharmaceutical industry's "14th Five-Year Plan" and the national innovation development strategy, the company aims to build a research and development innovation system with international first-class capabilities in new drug development and generic drug technology. It also aims to expand its sales network and actively explore high-end regulated markets in the United States, Japan, Europe, and other regions, striving to become a globally competitive specialty pharmaceutical company in the future.